SLC7A11 and neoplasm: The combination of ursolic acid and sorafenib inhibits SLC7A11 and reduces GSH synthesis, while significantly increasing lipid peroxidation levels, inducing ferroptosis in cells, and reversing drug resistance in liver cancer cells, thereby exhibiting significant antitumor activity and providing a new therapeutic strategy for tumor treatment.